| Whole antibody|
| Activated factor IX, factor X|
Emicizumab (ACE910) is an investigational monoclonal antibody for the treatment of haemophilia A, being developed by Chugai. A Phase I clinical trial found that it was well tolerated by healthy subjects.
Emicizumab binds to both the activated coagulation factor IX and to factor X, mediating the activation of the latter. This is normally the function of coagulation factor VIII, which is missing in haemophilia A patients.